Spyre Therapeutics (SYRE) Retained Earnings: 2015-2025
Historic Retained Earnings for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to -$1.1 billion.
- Spyre Therapeutics' Retained Earnings fell 20.07% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 20.07%. This contributed to the annual value of -$972.4 million for FY2024, which is 27.21% down from last year.
- As of Q3 2025, Spyre Therapeutics' Retained Earnings stood at -$1.1 billion, which was down 0.00% from -$1.1 billion recorded in Q2 2025.
- Spyre Therapeutics' 5-year Retained Earnings high stood at -$294.2 million for Q1 2021, and its period low was -$1.1 billion during Q2 2025.
- Over the past 3 years, Spyre Therapeutics' median Retained Earnings value was -$847.1 million (recorded in 2024), while the average stood at -$848.4 million.
- Data for Spyre Therapeutics' Retained Earnings shows a maximum YoY crashed of 82.03% (in 2024) over the last 5 years.
- Over the past 5 years, Spyre Therapeutics' Retained Earnings (Quarterly) stood at -$341.8 million in 2021, then dropped by 24.52% to -$425.6 million in 2022, then slumped by 79.60% to -$764.4 million in 2023, then decreased by 27.21% to -$972.4 million in 2024, then dropped by 20.07% to -$1.1 billion in 2025.
- Its last three reported values are -$1.1 billion in Q3 2025, -$1.1 billion for Q2 2025, and -$1.0 billion during Q1 2025.